Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency
Go back to Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 438.55 +2.84 (0.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $435.71 | 52 Week High | $134.71 | |||
| Open | $437.51 | 52 Week Low | $73.31 | |||
| Day High | $440.19 | P/E | N/A | |||
| Day Low | $435.21 | EPS | $-1.98 | |||
| Volume | 207,884 | |||||
